Haematology and Acute Leukaemia
Clinical research activity is centred on relapsed acute leukaemia, with attention to treatment-resistant disease and the need for new cellular approaches in paediatric and hospital-based care.
- Relapsed acute leukaemia
- Paediatric haematologic malignancies
- Refractory blood cancers
The sponsor’s research interest in this area reflects a focus on difficult-to-treat leukaemic disease within a specialised clinical setting in Athens.
Cellular Immunotherapy
The funded trial activity is directed toward CAR T-cell therapy, particularly CD19-targeted cellular treatment derived from donor cells for haematological cancer.
- CAR T-cell therapy
- CD19-targeted immunotherapy
- Donor-derived cellular products
This area highlights interest in advanced immune-based oncology and the clinical application of engineered cellular products in acute leukaemia.
Transplant-Related Complications
Research also addresses graft-versus-host disease, including both acute GVHD and chronic GVHD, in the context of donor-cell infusion and post-treatment immune effects.
- Acute graft-versus-host disease
- Chronic graft-versus-host disease
- Allogeneic cellular therapy
These interests place emphasis on immune compatibility and treatment-related toxicity in cell-based oncology.
Cell Processing and Manufacturing
The trial portfolio includes evaluation of CAR-T cell generation using the CliniMACS Prodigy platform, indicating interest in the technical and clinical aspects of cell preparation.
- CAR-T cell manufacturing
- Automated cell processing
- Product characterisation
This reflects a therapeutic focus on the practical delivery of advanced cell therapy within a hospital-based research environment.
